Overall survival, the primary endpoint of the study, was significantly worse for users of non-aspirin NSAIDs as compared to NSAID non-users (hazard ratio, 1.47; 95% CI, 1.31-1.65; p <.0001). The median overall survival was 11.6 versus 21.1 months for those groups, respectively.
Likewise, PFS was significantly worse for non-aspirin NSAID users versus NSAID non-users (hazard ratio, 1.29; 95% CI, 1.16-1.44; p <.0001), investigators reported.
For aspirin users, there was no significant difference versus NSAID non-users in either overall survival (hazard ratio, 1.0; 95% CI, 0.86-1.18; p=.9567) or PFS (hazard ratio, 1.07; 95% CI, 0.93-1.22; p=.3515), according to data from the study.
Also see - RCC: Fat linked with increased death risk
These findings contrast with what has been seen in colorectal cancer, where there is increasing interest in the role of NSAIDs as anti-tumor agents, investigators said. Clinical trials have suggested a modest benefit of NSAIDs in preventing colorectal adenoma recurrence.
There have been limited studies to date on the impact of NSAIDs in RCC, but only in patients with localized, rather than metastatic disease, according to investigators.
Similarly, an analysis of the Nurses’ Health Study and the Health Professionals Follow-up study showed an increased risk of RCC with longer use of non-aspirin NSAIDs, but not for aspirin (Arch Intern Med 2011; 171:1487-93).
More from Urology Times: